Experimental combo targets tough lung cancer

NCT ID NCT07153055

Recruiting now Disease control Sponsor: Misty Shields Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two drugs, lurbinectedin and osimertinib, is safe and effective for a rare type of lung cancer called transformed small cell lung cancer. The study will enroll 16 adults whose cancer has changed from a common form to this more aggressive type. Researchers will monitor side effects and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lurbinectedin and osimertinib
What this could lead to: If it works, this could point toward a new treatment option for a rare and aggressive lung cancer that has few effective therapies.
What could go wrong: This is a very early, small trial with only 16 participants, so results may not apply broadly. The drug combination may cause serious side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER ( SCLC ) TRANSFORMED SMALL CELL LUNG CANCER

Contacts and locations

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.